Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients
Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients
复制标题
DOI：
10.1177/0961203315603140
复制
发表时间：
2016-02-01
期刊：
影响因子：
2.6
通讯作者：
Inanc, M.
中科院分区：
文献类型：
--
作者：
Demir, S.;Artim-Esen, B.;Inanc, M.
背景/目的系统性红斑狼疮 (SLE) 患者的心血管疾病 (CVD) 发病率增加，心血管疾病是死亡的主要原因之一。本研究的目的是确定 SLE 患者代谢综合征 (MetS) 和 CVD 的频率，并调查这些与 SLE 临床特征之间的联系。 方法 根据国家胆固醇教育计划成人治疗小组 III (NCEP ATP III) 的定义，对总共 311 名 SLE 患者连续评估累积器官损伤（SDI/SLICC 评分）、CVD 和 MetS 病史。从病历中收集SLE患者的临床资料。结果患者的平均年龄为40.213.4岁，其中89%为女性。 CVD 和 MetS 的发生率分别为 15.2% 和 19%。在这个 SLE 队列中，年龄增加、累积损伤、疾病持续时间和 CVD 与 MetS 相关。 CVD与病程、累积损伤、心包炎、血液受累、淋巴细胞减少、血小板减少、神经受累和抗磷脂抗体（aPL）阳性相关。羟氯喹 (HCQ) 的使用被发现是 CVD 的保护因素。 结论 在 SLE 患者中，MetS 与 CVD 相关，并且两者均随着疾病持续时间而增加。发生 MetS 和/或 CVD 的患者累积器官损伤增加。 SLE 的某些临床特征和 aPL 的存在也与 CVD 相关。 HCQ 对 CVD 有显着的保护作用。预防MetS和长期使用HCQ可能有利于改善SLE的预后。
Background/Purpose Patients with systemic lupus erythematosus (SLE) have increased rates of cardiovascular disease (CVD) that are one of the major causes of mortality. The aim of this study was to determine the frequencies of metabolic syndrome (MetS) and CVD in SLE patients and investigate the link between these and clinical features of SLE.Methods A total of 311 SLE patients were consecutively assessed for cumulative organ damage (SDI/SLICC scores), history of CVD and MetS as defined by the National Cholesterol Educational Program Adult Treatment Panel III (NCEP ATP III). Clinical data of SLE patients were collected from the records.Results The mean age of the patients was 40.213.4 years and 89% were female. The frequencies of CVD and MetS were 15.2% and 19%, respectively. In this SLE cohort increased age, cumulative damage, disease duration and CVD were associated with MetS. CVD was associated with disease duration, cumulative damage, pericarditis, hematologic involvement, lymphopenia, thrombocytopenia, neurological involvement and antiphospholipid antibody (aPL) positivity. Hydroxychloroquine (HCQ) use was found as a protective factor for CVD.Conclusion In SLE patients, MetS was associated with CVD and both increased with disease duration. Patients who developed MetS and/or CVD had increased cumulative organ damage. Certain clinical features of SLE and the presence of aPL were also associated with CVD. There was a significant protective effect of HCQ from CVD. The prevention of MetS and long-term use of HCQ may be beneficial in improving the prognosis of SLE.